1. ALL of the following are potential complications of poorly controlled type 2 diabetes mellitus, EXCEPT?

2. Fill in the blank: Glycated end-products are the result of too much ______ in the blood.

3. The United States Food and Drug Administration 2008 guidance requires the study of type 2 diabetes medications to determine which of the following:

4. Which of the following DPP-4 inhibitors are safe in patients with atherosclerotic cardiovascular disease (ASCVD)?

5. Which of the following DPP-4 inhibitors are safe in patients with heart failure?

6. Which of the following GLP-1 receptor agonists provide ASCVD risk reduction?

7. Which of the following SGLT-2 inhibitors was studied to determine if there was benefit in chronic kidney disease even when patients don't have type 2 diabetes mellitus?

8. Select the BEST T2DM medication to add for ASCVD risk reduction for the following patient: 65 year old male with a past medical history of MI (6 months ago) and heart failure with reduced ejection fraction (HFrEF). His pertinent labs are HgbA1C = 6.5% and estimated glomerular filtration rate (eGFR) = 25 mL/min.

9. Select the BEST T2DM medication to as a treatment for reduction in heart failure morbidity and mortality: 70 year old male with a past medical history of hypertension and heart failure with reduced ejection fraction (HFrEF). He does NOT have T2DM. His pertinent labs are estimated glomerular filtration rate (eGFR) = 60 mL/min.

10. Select the BEST T2DM medication to as a treatment for additional glucose control in the following patient: 58 year old obese male with a past medical history of hypertension, hyperlipidemia and a previous transient ischemic attack (TIA). He has a 30 pack-year history of smoking. His pertinent labs are HgbA1C = 8.5% and estimated glomerular filtration rate (eGFR) = 25 mL/min.

« Return to Activity